Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
ITCI reported earnings recently. https://finance.yahoo.com/news/intra-cellular-therapies-repo....

Their new drug they launched in March had it's second quarter of sales. $2 million in Q1 and $7 million in Q2. The name of the drug is CAPLYTA and it's used to treat schizophrenia but does not come with some of the other side effects of the drugs currently on the market, namely, weight gain. They also plan to submit a sNDA for Bipolar Depression, which is a much larger market. Their trial studies had similar results as the trials for schizophrenia, where lower doses were not effective, but higher doses were, while still maintaining a safety profile with little to no side effects. I own a small position in this stock as I watch their commercial success unfold... or falter. Would like to hear feedback on them for anyone who is familiar with them.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.